Press Releases

Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results

WALTHAM, MA – March 15, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.

Thursday March 17th, 8:30 a.m. (ET)

Dial in (domestic):                  877-324-1976

Dial in (international):            631-291-4550

Conference ID:                        62665317

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

 

About Interleukin Genetics.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage […]

Interleukin Genetics and Metagenics Enter into Agreement to Incorporate PerioPredict® into Metagenics’ Employee Benefit Plan

WALTHAM, MA – February 18, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, and Metagenics, Inc., a global pioneer in science-based nutrition and wellness, today announced the signing of an agreement to provide Interleukin’s PerioPredict test to Metagenics’ employees as part of an enhanced employee benefits program.  PerioPredict will be used to identify individuals who may benefit from reduction of their systemic inflammatory burden as an approach to enhance prevention and management of chronic diseases.

Under the terms of the agreement, Interleukin will provide genetic testing and patient education to Metagenics employees, as well as dental professional support to their dental providers.

“We are […]

Interleukin Genetics Reports Third Quarter 2015 Financial Results

WALTHAM, Mass. – November 12, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.

“Since joining Interleukin Genetics in April, I have been focused on developing a strategic and operational plan that will lay the groundwork for driving market adoption of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to over-produce inflammation.  Elevated inflammation is implicated in numerous chronic diseases.” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.

“We are encouraged by the reception of our enhanced positioning that outlines medical value for managing inflammation through practical dental interventions”, Mr. Carbeau continued.  “Medical studies now document the role of systemic inflammation in […]

Interleukin Genetics Reports Second Quarter 2015 Financial Results

Company to Host Conference Call Today at 8:30 a.m. ET

WALTHAM, Mass. – August 14, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.

“Interleukin Genetics is advancing on its mission to prevent and more cost-effectively manage chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “We have enhanced the positioning of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to produce inflammation, to target patients with chronic conditions such as diabetes and cardiovascular disease who will benefit from increased dental care. Engaging these high-risk Individuals provides significant leverage to improve wellness and lower costs, builds on the strong foundation […]

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results

WALTHAM, Mass. – August 7, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company’s website at 52.2.148.42.  The webcast will be archived following the call at 52.2.148.42.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and […]

Interleukin Genetics and NYU School of Medicine Enter Into License Agreement to Enable Commercialization of a Genetics-Based Test for Osteoarthritis

New test will identify individuals at increased risk for progression of osteoarthritis, the most common adult joint disease

WALTHAM, MA and NEW YORK – July 15, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) and NYU School of Medicine announced today they signed a license agreement to develop the first  genetic test of its kind to identify individuals at increased risk for progression of osteoarthritis (OA) and related complications, such as knee replacement. The agreement pertains to U.S. patent application No. 12/435,260 titled “Detecting Genetic Predisposition to Osteoarthritis Associated Conditions,” which is jointly owned by NYU School of Medicine and Interleukin Genetics.

OA is the most common adult joint disease, increasing in frequency and severity in all aging populations. The estimated prevalence in […]

Interleukin Genetics to Present at 2015 Marcum MicroCap Conference

WALTHAM, MA – May 19, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City.

The presentation will be webcast live and may be accessed at http://wsw.com/webcast/marcum3/iliu/index.aspx or by visiting the Company’s website at 52.2.148.42. The webcast will also be available on the Company’s website for a limited period of time following the conference.
 
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic […]

Interleukin Genetics Reports First Quarter 2015 Financial Results

Company to Host Conference Call Today at 8:30 a.m. ET

WALTHAM, MA – May 15, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal first quarter of 2015 ended March 31, 2015.
“Interleukin Genetics’ highest priority in the coming months is to maximize the commercial potential of PerioPredict®, our genetics-based risk assessment test for severe periodontitis,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “Going forward, we will continue to place significant emphasis and efforts on increasing the adoption and awareness of PerioPredict, and our new partnership with Employee Benefit Consulting Group (EBCG) is a key element of our strategy.  As a channel partner, EBCG has unique expertise in the U.S. insurance market […]

Interleukin Genetics Announces Conference Call to Discuss First Quarter 2015 Financial Results

WALTHAM, MA – May 11, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Friday, May 15, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s first quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international).  The live webcast will also be available at the Investors section of the Company’s website at 52.2.148.42.  The webcast will be archived following the call at 52.2.148.42.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and to […]

Interleukin Genetics Granted Key European Patent Covering Inherent Health® Weight Management Genetic Test

WALTHAM, MA, April 15, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company’s Inherent Health® Weight Management Genetic Test. The granted patent, entitled “Genetic Markers for Weight Management and Methods of Use Thereof,” has claims covering methods of determining a subject’s metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject’s metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are […]